Advances in Clinical and Experimental Medicine

Adv Clin Exp Med
Impact Factor (IF) – 1.514
Index Copernicus (ICV 2018) – 157.72
MNiSW – 40
Average rejection rate – 84.38%
ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download PDF

Advances in Clinical and Experimental Medicine

2014, vol. 23, nr 2, March-April, p. 253–257

Publication type: original article

Language: English

Risk Factors for Intraaortic Balloon Pump Use in Coronary Artery Bypass Surgery

Habib Cakir1,A,B,C,D,E,F, Hasan Uncu2,A,B,C, Ozcan Gur3,B,C,D,E,F, Demet Ozkaramanli Gur4,C,D,E, Ismail Yurekli1,C,D,E,F, Ozsoyler Ibrahim2,A,B,C,D,E

1 Department of Cardiovascular Surgery, Katip Celebi University ataturk Education and Training Hospital, Izmir, Turkey

2 Department of Cardiovascular Surgery, adana Numune Education and Training Hospital, Turkey

3 Department of Cardiovascular Surgery, Namik Kemal University Medicine faculty, Tekirdag, Turkey

4 Department of Cardiology, Tekirdag State Hospital, Turkey


Objectives. The study was aimed at investigating the risk factors of using an intraaortic balloon pump (IabP) in coronary artery bypass surgery and presenting the authors’ clinical experience of IabP use.
Material and Methods. The study included 1094 patients who underwent coronary artery bypass surgery at the authors’ clinic between January 2009 and December 2011. a comparison was made between 17 patients in whom an IabP was used and 1077 patients in whom it was not used.
Results. an intraaortic balloon pump was used in 17 patients (1.55%) out of 1094 patients who underwent isolated coronary artery bypass surgery. The ratio of patients who had had preoperative myocardial infarction within the preceding 30 days, left main coronary artery stenosis of more than 50% and emergency surgery in Group 1 were higher than in Group 2 (p < 0.05). The total cardiopulmonary bypass time of Group 1 was found to be longer than that of Group 2 (p < 0.05). The demand for inotropics after weaning from cardiopulmonary bypass was greater in Group 1 than in Group 2 (p < 0.05). The need for reoperation (because of bleeding) was higher in Group 1 than in Group 2 (p < 0.05). The patients’ stay on the intensive care unit was longer in Group 1 than in Group 2 (p < 0.05). Mortality rates were 29.4% in Group 1 and 1.2% in Group 2 (p < 0.05).
Conclusion. Preoperative myocardial infarction within the preceding 30 days, left main coronary artery stenosis of more than 50%, emergency surgery and long cardiopulmonary bypass time are important risk factors for IabP use in coronary artery bypass surgery.

Key words

intraaortic balloon pump, coronary artery bypass surgery, mortality.

References (13)

  1. Baskett RJF, Ghali WA, Maitland A, Hirsh GM: The intraaortic balloon pump in cardiac surgery. ann Thorac Surg 2002, 74, 1276–1287.
  2. Rao V: Condition critical: can mechanical support prevent death due to postcardiotomy shock? J Card Surg 2006, 21, 238–239.
  3. Richenbacher WE, Pierce WS: Treatment of heart failure: assisted circulation. In: Heart disease. a textbook of cardiovascular medicine. Eds.: braunwald E, Zipes DP, Libby P. Saunders, Philadelphia 2001, 6th ed., 600–614.
  4. Miceli A, Duggan JMS, Capoun R, Romeo F, Caputo MAngelini GD: a Clinical Score to Predict the Need for Intraaortic balloon Pump in Patients Undergoing Coronary artery bypass Grafting. ann Thorac Surg 2010, 90, 522–526.
  5. Miceli A, Fiorani B, Danesi TH, Melina G, Sinatra R: Prophylactic intra-aortic balloon pump in high-risk patients undergoing coronary artery bypass grafting: a propensity score analysis. Interact Cardiovasc Thorac Surg 2009, 9, 291–294.
  6. Creswell LL, Rosenbloom M, Cox JL, Ferguson TB Sr, Kouchoukos NT, Spray TL: Intraaortic balloon counterpulsation: patterns of usage and outcome in cardiac surgery patients. ann Thorac Surg 1992, 54, 11–20.
  7. Parissis H, Soo A, Alao B: Intra-aortic balloon pump: literature review of risk factors related to complications of the intraaortic balloon pump. J Cardiothorac Surg 2011, 6, 147.
  8. Vales L, Kanei Y, Ephrem G, Misra D: Intra-aortic balloon pump use and outcomes with current therapies. J Invasive Cardiol 2011, 23, 116–119.
  9. Rastan AJ, Tillmann E, Subramanian S, Lehmkuhl L, Funkat AK, Leontyev S: Visceral arterial compromise during intra-aortic balloon counterpulsation therapy. Circulation 2010, 14, 122, 92–99.
  10. Colyer W R, Moore JA, Burket MW, Cooper CJ: Intraaortic balloon pump insertion after percutaneous revascularization in patients with severe peripheral vascular disease. Cathet Cardiovasc Diagn 1997, 42, l–6.
  11. Iverson LI, Herfindahl G, Ecker RR, Young JN, Ennix CL, Lee J: Vascular complications of intraaortic balloon counterpulsation. am J Surg 1987, 154, 99–103.
  12. Arafa OE, Pedersen TH, Svennevig JL, Fosse E, Geiran OR: Intraaortic balloon pump in open heart operations: 10-year follow-up with risk analysis. ann Thorac Surg 1998, 65, 741–747.
  13. Torchiana DF, Hirsh G, Buckley MJ, Hahn C, Allyn JW, Akins CW: Intraaortic balloon pumping for cardiac support: trends in practice and outcome, 1968 to 1995. J Thorac Cardiovasc Surg 1997, 113, 758–764.